Korean Society of Heart Failure Guidelines for the Management of Heart Failure: Management of the Underlying Etiologies and Comorbidities of Heart Failureopen access
- Authors
- Park, Sang Min; Lee, Soo Youn; Jung, Mi-Hyang; Youn, Jong-Chan; Kim, Darae; Cho, Jae Yeong; Cho, Dong-Hyuk; Hyun, Junho; Cho, Hyun-Jai; Park, Seong-Mi; Choi, Jin-Oh; Chung, Wook-Jin; Kang, Seok-Min; Yoo, Byung-Su
- Issue Date
- Jul-2023
- Publisher
- Korean Society of Heart Failure
- Keywords
- Comorbidity; Disease management; Guideline; Heart failure
- Citation
- International Journal of Heart Failure, v.5, no.3, pp 127 - 145
- Pages
- 19
- Journal Title
- International Journal of Heart Failure
- Volume
- 5
- Number
- 3
- Start Page
- 127
- End Page
- 145
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90972
- DOI
- 10.36628/ijhf.2023.0016
- ISSN
- 2636-154X
2636-1558
- Abstract
- Most patients with heart failure (HF) have multiple comorbidities, which impact their quality of life, aggravate HF, and increase mortality. Cardiovascular comorbidities include systemic and pulmonary hypertension, ischemic and valvular heart diseases, and atrial fibrillation. Non-cardiovascular comorbidities include diabetes mellitus (DM), chronic kidney and pulmonary diseases, iron deficiency and anemia, and sleep apnea. In patients with HF with hypertension and left ventricular hypertrophy, renin-angiotensin system inhibitors combined with calcium channel blockers and/or diuretics is an effective treatment regimen. Measurement of pulmonary vascular resistance via right heart catheterization is recommended for patients with HF considered suitable for implantation of mechanical circulatory support devices or as heart transplantation candidates. Coronary angiography remains the gold standard for the diagnosis and reperfusion in patients with HF and angina pectoris refractory to antianginal medications. In patients with HF and atrial fibrillation, long-term anticoagulants are recommended according to the CHA2DS2-VASc scores. Valvular heart diseases should be treated medically and/or surgically. In patients with HF and DM, metformin is relatively safer; thiazolidinediones cause fluid retention and should be avoided in patients with HF and dyspnea. In renal insufficiency, both volume status and cardiac performance are important for therapy guidance. In patients with HF and pulmonary disease, beta-blockers are underused, which may be related to increased mortality. In patients with HF and anemia, iron supplementation can help improve symptoms. In obstructive sleep apnea, continuous positive airway pressure therapy helps avoid severe nocturnal hypoxia. Appropriate management of comorbidities is important for improving clinical outcomes in patients with HF. Copyright © 2023. Korean Society of Heart Failure.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - ETC > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/90972)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.